Natura still struggling with Hong Kong protests, eyes China in long run
By Gabriela Mello
SAO PAULO, Nov 14 (Reuters) - Brazilian cosmetics firm Natura&Co NATU3.SA is still facing challenges in Hong Kong, where both its Body Shop and Aesop brands have been affected by months of violent protests, and does not expect the situation to improve in the short-term, executives said on Thursday.
"Hong Kong is an important market for The Body Shop and Aesop, especially as we do not yet have a physical presence in China because of the animal testing," Natura's chairman, Roberto Marques, told analysts and investors in a call to discuss third-quarter results.
"A mid-long term solution is finding a way to increase our presence in China while keeping our values," Marques said, adding Natura recently entered the Malaysian market and is pleased with initial results.
Despite the ongoing turmoil in Hong Kong, the Body Shop brand has been performing well, with accelerating top-line growth, particularly in the UK, Middle East and Latin America, Chief Executive João Paulo Ferreira said.
Both executives declined to discuss Natura's integration with Avon Products AVP.N, but emphasized the companies continue on track to conclude the transaction in the first quarter of 2020.
Almost two years after acquiring the Body Shop brand from L'Oreal in a 1 billion-euro transaction, Natura struck in May a deal with Avon to create the world's fourth-largest beauty group.
The deal was approved by Brazilian antitrust body Cade on Nov. 6 and by shareholders of both companies on Nov. 13. "We've still lack antitrust approval by a handful of remaining jurisdictions, but we are on track and excited with recent progress made," Marques said.
Shares in Natura were little changed in early afternoon trade at 32.06 reais.
On Wednesday night, the company posted a net income of 68.6 million reais, missing market expectations.
(Reporting by Gabriela Mello, Editing by Franklin Paul and Steve Orlofsky)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.